Frequency and Pattern of Dyslipidemia in Patient Presenting with Type II Diabetes at Tertiary Care Hospital

Fauzia Asmat; Shamimah Hanif; Abdul Malik; Sarfraz Ahmad; Zaheer Shah; Mir Usman Shah; Syed Ehsanullah; Sana Ullah Kakar

doi:10.70749/ijbr.v3i6.1798

Authors

Fauzia Asmat Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Shamimah Hanif Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Abdul Malik Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Sarfraz Ahmad Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Zaheer Shah Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Mir Usman Shah Department of Medicine, Sandeman Provincial Hospital, Quetta, Balochistan, Pakistan.
Syed Ehsanullah Department of Medicine, Bolan Medical College Hospital, Quetta, Balochistan, Pakistan.
Sana Ullah Kakar Balochistan Institute of Psychiatry and Behavioral Sciences (BIPBS), Quetta, Balochistan, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i6.1798

Keywords:

Dyslipidemia, Type II Diabetes Mellitus, HDL-C, LDL-C, HbA1c, Cardiovascular Risk, Lipid Abnormalities

Abstract

Background: Dyslipidemia is a major modifiable cardiovascular risk factor frequently seen in type II diabetes mellitus (T2DM) due to insulin resistance and poor glycemic control. This study investigates the frequency and pattern of dyslipidemia in T2DM patients at a tertiary care hospital. Objective: to ascertain the distribution and prevalence of dyslipidemia in individuals with type II diabetes and investigate its correlation with age, gender, HbA1c levels, and diabetes duration. Methodology: 150 individuals with a diagnosis of type 2 diabetes participated in a cross-sectional study. Lipid profiles, HbA1c values, and the length of diabetes were all gathered. Individuals with concomitant lipid problems or those undergoing lipid-lowering medication were not included. Results: The most common anomaly was low HDL-C (69.3%), which was followed by hypertriglyceridemia (60.7%) and high LDL-C (65.3%). Patients with prolonged disease duration and poor glycemic control were more likely to have dyslipidemia. Conclusion: In patients with type 2 diabetes, dyslipidemia is quite common and closely linked to both the length of diabetes and poor HbA1c control. To lower cardiovascular risk, early screening and comprehensive management are crucial.

Downloads

Download data is not yet available.

References

Al-Adsani, A., Memon, A., & Suresh, A. (2004). Pattern and determinants of dyslipidaemia in type 2 diabetes mellitus patients in Kuwait. Acta Diabetologica, 41(3), 129-135.

https://doi.org/10.1007/s00592-004-0156-9

International diabetes federation diabetes atlas. 7th ed.

https://www.diabetesatlas.org/

HAYAT, S., PATEL, B., KHATTAR, R., & MALIK, R. (2004). Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clinical Science, 107(6), 539-557.

https://doi.org/10.1042/cs20040057

American Diabetes Association. (2004). Dyslipidemia management in adult with diabetes. Diabetes Care. Diabetes Care, 27(suppl_1), s68-s71.

https://doi.org/10.2337/diacare.27.2007.s68

Singh, G., & Kumar, A. (2011). Relationship among HbAlc and lipid profile in Punajbi type 2 diabetic population. Journal of Exercise Science and Physiotherapy, 7(2), 99.

https://doi.org/10.18376//2011/v7i2/67614

Langsted, A., & Nordestgaard, B. G. (2011). Nonfasting lipids, lipoproteins, and Apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen general population study. Clinical Chemistry, 57(3), 482-489.

https://doi.org/10.1373/clinchem.2010.157164

UK, N. C. G. C. (2014). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., Chapman, M. J., Cobbaert, C., Descamps, O. S., Von Eckardstein, A., Kamstrup, P. R., Pulkki, K., Kronenberg, F., Remaley, A. T., Rifai, N., … Langlois, M. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration Cutpoints—A joint consensus statement from the European atherosclerosis society and European Federation of clinical chemistry and laboratory medicine. Clinical Chemistry, 62(7), 930-946.

https://doi.org/10.1373/clinchem.2016.258897

Qi, L., Ding, X., Tang, W., Li, Q., Mao, D., & Wang, Y. (2015). Prevalence and risk factors associated with Dyslipidemia in Chongqing, China. International Journal of Environmental Research and Public Health, 12(10), 13455-13465.

https://doi.org/10.3390/ijerph121013455

Bhandari, G. P., Angdembe, M. R., Dhimal, M., Neupane, S., & Bhusal, C. (2014). State of non-communicable diseases in Nepal. BMC Public Health, 14(1), 1-9.

https://doi.org/10.1186/1471-2458-14-23

Pokharel, D. R., Khadka, D., Sigdel, M., Yadav, N. K., Acharya, S., Kafle, R., Sapkota, R. M., & Sigdel, T. (2017). Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes. BMC Research Notes, 10(1).

https://doi.org/10.1186/s13104-017-2465-4

Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013). Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs, 73(4), 327-339.

https://doi.org/10.1007/s40265-013-0023-5

Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005). Type 2 diabetes as a “Coronary heart disease equivalent”. Diabetes Care, 28(12), 2901-2907.

https://doi.org/10.2337/diacare.28.12.2901

Talat, N., Aamir, K., Gulsena, M., Bilal, B. Y., & MA, C. (2003). Dyslipidemias in type II diabetes mellitus patients in a teaching hospital of Lahore, Pakistan. Pak J Med Sci, 19(4), 283–286.

Dm, N. (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 49, 1711-1721.

https://cir.nii.ac.jp/crid/1570291225513645696

Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology, 5(3), 150-159.

https://doi.org/10.1038/ncpendmet1066

Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology, 5(3), 150-159.

https://doi.org/10.1038/ncpendmet1066

Goldberg, I. J. (2001). Diabetic Dyslipidemia: Causes and consequences. Journal of Clinical Endocrinology & Metabolism, 86(3), 965-971.

https://doi.org/10.1210/jc.86.3.965

American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care, 46(Suppl 1), S123–S138.

Khan SA, Arif M, Bano S, Khan NA. Dyslipidemia in type 2 diabetes mellitus patients in a tertiary care hospital, Peshawar. J Ayub Med Coll Abbottabad. 2017;29(1):31–35.

Agarwal AK, Singh S. Dyslipidemia in newly diagnosed type 2 diabetes mellitus patients: pattern and predictors. J Assoc Physicians India. 2016;64(11):14–17.

Anwar M, Iqbal SP, Khurshid M. Gender differences in dyslipidemia patterns among diabetic patients. Diabetes Metab Syndr. 2019;13(2):1235–1239.

Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England journal of medicine, 339(4), 229-234.

https://doi.org/10.1056/NEJM199807233390404

Yadav S, Bhattarai D, Yadav NK. Prevalence of dyslipidemia among type 2 diabetes patients in Eastern Nepal. J Nepal Med Assoc. 2020;58(229):275–279.

Younis BB, Riaz M, Altaf M. Frequency of dyslipidemia in type 2 diabetics. Saudi Med J. 2015;36(10):1260–1263.

Kumar A, Singh R, Singh N. Correlation of lipid profile with HbA1c in T2DM. Int J Contemp Med Res. 2016;3(4):1006–1009.

UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet, 352(9131), 837-853.

https://doi.org/10.1016/S0140-6736(98)07019-6

American Diabetes Association. (2023). Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Suppl 1), S158–S190.

Baig M, Saeed M, Shafiq M, et al. Awareness of dyslipidemia and its consequences in diabetic patients: a multicenter study. J Family Med Prim Care. 2020;9(2):987–991.

Toth, P. (2016). Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vascular Health and Risk Management, 171.

https://doi.org/10.2147/vhrm.s104369